Core Viewpoint - Huadong Medicine (000963.SZ) announced that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd. (referred to as "Daer Bio"), has received approval from the U.S. Food and Drug Administration (FDA) for the clinical trial application of the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Group 1 - Daer Bio's DR10624 is a first-in-class long-acting tri-specific agonist targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R) [1] - The drug is designed with a chimeric peptide segment targeting GLP-1R/GCGR fused with an engineered IgG1 Fc, incorporating a recombinant FGF21 mutant at the C-terminus of Fc [1]